308 lines
12 KiB
Plaintext
308 lines
12 KiB
Plaintext
English French Notes Complete/Exclude
|
|
FIRST COURSE OF TREATMENT - RADIATION
|
|
38. REGIONAL DOSE (cGy)...........:
|
|
39. BOOST DOSE (cGy)..............:
|
|
40. INTRA-OPERATIVE RADIATION
|
|
41. CONCURRENT CHEMOTHERAPY.......:
|
|
FIRST COURSE OF TREATMENT - CHEMOTHERAPY
|
|
42. TYPE OF CHEMOTHERAPEUTIC AGENTS ADMINISTERED:
|
|
43. INTRAPERITONEAL CHEMOTHERAPY..:
|
|
44. CHEMOTHERAPEUTIC TOXICITY.....:
|
|
45. CHEMOTHERAPY/SURGERY SEQUENCE.:
|
|
FIRST COURSE OF TREATMENT - IMMUNOTHERAPY
|
|
46. ADMINISTRATION OF INTERFERON..:
|
|
TREATMENT COMPLICATIONS
|
|
CASE REGISTRATION
|
|
48. INITIALS OF CASE ABSTRACTOR...:
|
|
49. DATE CASE WAS ABSTRACTED......:
|
|
The Accession Year is not 2000.
|
|
2000 Patient Care Evaluation Study of Hepatocellular Cancers
|
|
1. FACILITY ID NUMBER (FIN)
|
|
5. PLACE OF BIRTH
|
|
6. DATE OF BIRTH
|
|
8. SPANISH ORIGIN
|
|
10. PRIMARY PAYER AT DIAGNOSIS
|
|
1. FACILITY ID NUMBER (FIN)
|
|
5. PLACE OF BIRTH
|
|
6. DATE OF BIRTH
|
|
8. SPANISH ORIGIN
|
|
1. FACILITY ID NUMBER (FIN)......:
|
|
2. ACCESSION NUMBER..............:
|
|
3. SEQUENCE NUMBER...............:
|
|
9 4. POSTAL CODE AT DIAGNOSIS......
|
|
7 5. PLACE OF BIRTH................
|
|
6. DATE OF BIRTH.................:
|
|
9 8. SPANISH ORIGIN................
|
|
18 10. PRIMARY PAYER AT DIAGNOSIS....
|
|
11. CLASS OF CASE
|
|
13. CONDITIONS PRESENT AT INITIAL DIAGNOSIS
|
|
14. ALCOHOL CONSUMPTION
|
|
15. TUMOR MARKERS
|
|
16. TESTS RELATED TO LIVER FUNCTION
|
|
17. RADIOLOGICAL EVALUATION
|
|
18. DEFINITIVE DIAGNOSIS
|
|
19. DATE OF INITIAL DIAGNOSIS
|
|
22. DIAGNOSTIC CONFIRMATION
|
|
TUMOR IDENTIFICATION
|
|
11. CLASS OF CASE.................:
|
|
1000 ORAL CONTRACEPTIVES..........
|
|
1001 ESTROGEN REPLACEMENT.........
|
|
13. CONDITIONS PRESENT AT INITIAL DIAGNOSIS:
|
|
1012 14. ALCOHOL CONSUMPTION...........
|
|
15. TUMOR MARKERS:
|
|
16. TESTS RELATED TO LIVER FUNCTION:
|
|
17. RADIOLOGICAL EVALUATION:
|
|
CT ARTERIAL PORTOGRAPHY:
|
|
1022 VASCULAR INVASION............
|
|
1023 BILOBAR DISEASE..............
|
|
1024 LYMPH NODES..................
|
|
1025 SIZE OF DOMINANT TUMOR (mm)..
|
|
1026 NUMBER OF TUMORS.............
|
|
SPIRAL CT:
|
|
1029 VASCULAR INVASION............
|
|
1030 BILOBAR DISEASE..............
|
|
1031 LYMPH NODES..................
|
|
1032 SIZE OF DOMINANT TUMOR (mm)..
|
|
1033 NUMBER OF TUMORS.............
|
|
INCREMENTAL CT:
|
|
1036 VASCULAR INVASION............
|
|
1037 BILOBAR DISEASE..............
|
|
1038 LYMPH NODES..................
|
|
1039 SIZE OF DOMINANT TUMOR (mm)..
|
|
1040 NUMBER OF TUMORS.............
|
|
1043 VASCULAR INVASION............
|
|
1044 BILOBAR DISEASE..............
|
|
1045 LYMPH NODES..................
|
|
1046 SIZE OF DOMINANT TUMOR (mm)..
|
|
1047 NUMBER OF TUMORS.............
|
|
1050 VASCULAR INVASION............
|
|
1051 BILOBAR DISEASE..............
|
|
1052 LYMPH NODES..................
|
|
1053 SIZE OF DOMINANT TUMOR (mm)..
|
|
1054 NUMBER OF TUMORS.............
|
|
1055 18. DEFINITIVE DIAGNOSIS..........
|
|
19. DATE OF INITIAL DIAGNOSIS.....:
|
|
22. DIAGNOSTIC CONFIRMATON........:
|
|
VASCULAR INVASION............: NA
|
|
BILOBAR DISEASE..............: NA
|
|
LYMPH NODES..................: NA
|
|
SIZE OF DOMINANT TUMOR (mm)..: Not performed
|
|
NUMBER OF TUMORS.............: Not performed
|
|
VASCULAR INVASION............: Unknown
|
|
BILOBAR DISEASE..............: Unknown
|
|
LYMPH NODES..................: Unknown
|
|
23. SIZE OF TUMOR
|
|
24. REGIONAL NODES EXAMINED
|
|
25. REGIONAL NODES POSITIVE
|
|
26. AJCC CLINICAL STAGE (cTNM)
|
|
27. AJCC PATHOLOGIC STAGE (pTNM)
|
|
28. STAGED BY
|
|
STAGE OF DISEASE AT DIAGNOSIS
|
|
29 23. SIZE OF TUMOR ................
|
|
33 24. REGIONAL NODES EXAMINED.......
|
|
32 25. REGIONAL NODES POSITIVE.......
|
|
26. AJCC CLINICAL STAGE (cTNM):
|
|
37.1 AJCC CLINICAL T..............
|
|
37.2 AJCC CLINICAL N..............
|
|
37.3 AJCC CLINICAL M..............
|
|
27. AJCC PATHOLOGIC STAGE (pTNM):
|
|
85 AJCC PATHOLOGIC T............
|
|
86 AJCC PATHOLOGIC N............
|
|
87 AJCC PATHOLOGIC M............
|
|
28. STAGED BY:
|
|
19 CLINICALLY STAGED BY.........
|
|
89 PATHOLOGICALLY STAGED BY.....
|
|
29. DATE OF FIRST COURSE OF TREATMENT
|
|
30. DATE OF INPATIENT ADMISSION
|
|
31. DATE OF INPATIENT DISCHARGE
|
|
32. DATE OF NON CANCER-DIRECTED SURGERY
|
|
33. NON CANCER-DIRECTED SURGERY
|
|
34. DATE OF CANCER-DIRECTED SURGERY
|
|
35. SURGICAL APPROACH
|
|
36. SURGERY OF PRIMARY SITE
|
|
37. RADIO-FREQUENCY DESTRUCTION OF TUMOR
|
|
39. SURGICAL MARGINS
|
|
40. DISTANCE OF TUMOR TO CLOSEST MARGIN
|
|
41. SURGERY OF REGIONAL SITE(S), DISTANT SITE(S), OR DISTANT LYMPH NODE(S)
|
|
42. SURGICAL TREATMENT OF RESIDUAL PRIMARY TUMOR
|
|
43. RECONSTRUCTION/RESTORATION-FIRST COURSE
|
|
44. DATE RADIATION STARTED
|
|
45. RADIATION THERAPY
|
|
46. DATE CHEMOTHERAPY STARTED
|
|
48. TYPE OF CHEMOTHERAPEUTIC AGENTS ADMINISTERED
|
|
49. ROUTE CHEMOTHERAPY ADMINISTERED
|
|
50. CHEMOTHERAPY/SURGERY SEQUENCE
|
|
OTHER THERAPY
|
|
51. DATE OTHER TREATMENT STARTED
|
|
52. OTHER TREATMENT
|
|
53. ARTERIAL EMBOLIZATION
|
|
54. DEATH WITHIN30 DAYS OF START OF INTIIAL COURSE OF THERAPY
|
|
FIRST COURSE OF TREATMENT
|
|
29. DATE OF FIRST COURSE OF
|
|
1 30. DATE OF INPATIENT ADMISSION...
|
|
1.1 31. DATE OF INPATIENT DISCHARGE...
|
|
32. DATE OF NON CANCER-DIRECTED
|
|
33. NON CANCER-DIRECTED SURGERY...:
|
|
34. DATE OF CANCER-DIRECTED
|
|
35. SURGICAL APPROACH.............:
|
|
36. SURGERY OF PRIMARY SITE.......:
|
|
37. RADIO-FREQUENCY DESTRUCTION OF
|
|
1056 37. RADIO-FREQUENCY DESTRUCTION OF TUMOR........................
|
|
38. ABLATION & RESECTION..........: Ablation & resection not administered
|
|
39. SURGICAL MARGINS..............:
|
|
40. DISTANCE OF TUMOR TO CLOSEST
|
|
1058 40. DISTANCE OF TUMOR TO CLOSEST MARGIN.......................
|
|
41. SURGERY OF OTHER REGIONAL
|
|
SITE(S), DISTANT SITE(S),
|
|
OR DISTANT LYMPH NODE(S).....:
|
|
42. SURGICAL TREATMENT OF RESIDUAL PRIMARY TUMOR:
|
|
FIRST COURSE.................:
|
|
44. DATE RADIATION STARTED........:
|
|
45. RADIATION THERAPY.............:
|
|
46. DATE CHEMOTHERAPY STARTED.....:
|
|
48. TYPE OF CHEMOTHERAPEUTIC AGENTS ADMINISTERED:
|
|
CISPLATIN....................: Unknown if recommended or administered
|
|
FUDR.........................: Unknown if recommended or administered
|
|
5-FU.........................: Unknown if recommended or administered
|
|
FU & LEUCOVORIN..............: Unknown if recommended or administered
|
|
IRINOTECAN (CPT-11)..........: Unknown if recommended or administered
|
|
MITOMYCIN C..................: Unknown if recommended or administered
|
|
OXALIPLATIN..................: Unknown if recommended or administered
|
|
GEMCITABINE..................: Unknown if recommended or administered
|
|
49. ROUTE CHEMOTHERAPY ADMIN......: NA
|
|
1069 49. ROUTE CHEMOTHERAPY ADMIN
|
|
50. CHEMOTHERAPY/SURGERY SEQUENCE.: No chemotherapy and/or no surgery
|
|
50. CHEMOTHERAPY/SURGERY SEQUENCE.: Chemotherapy before surgery
|
|
1070 50. CHEMOTHERAPY/SURGERY SEQUENCE.
|
|
OTHER THERAPY
|
|
51. DATE OTHER TREATMENT STARTED..:
|
|
52. OTHER TREATMENT...............:
|
|
1071 53. ARTERIAL EMBOLIZATION.........
|
|
1072 54. DEATH WITHIN 30 DAYS OF START OF INITIAL COURSE OF THERAPY.
|
|
55. DATE OF FIRST RECURRENCE
|
|
56. TYPE OF FIRST RECURRENCE
|
|
55. TYPE OF FIRST RECURRENCE
|
|
56. DATE OF FIRST RECURRENCE
|
|
70 55. DATE OF FIRST RECURRENCE
|
|
71 56. TYPE OF FIRST RECURRENCE
|
|
57. DATE OF LAST CONTACT OR DEATH
|
|
58. VITAL STATUS
|
|
59. CANCER STATUS
|
|
57. DATE OF LAST CONTACT OR DEATH..:
|
|
15 58. VITAL STATUS...................
|
|
59. CANCER STATUS..................:
|
|
1. FACILITY ID NUMBER (FIN)....:
|
|
2. ACCESSION NUMBER............:
|
|
3. SEQUENCE NUMBER.............:
|
|
4. POSTAL CODE AT DIAGNOIS.....:
|
|
5. PLACE OF BIRTH..............:
|
|
6. DATE OF BIRTH...............:
|
|
8. SPANISH ORIGIN..............:
|
|
10. PRIMARY PAYER AT DIAGNOSIS..:
|
|
TUMOR IDENTIFICATION
|
|
11. CLASS OF CASE...............:
|
|
ORAL CONTRACEPTIVES........:
|
|
ESTROGEN REPLACEMENT.......:
|
|
14. ALCOHOL CONSUMPTION.........:
|
|
15. TUMOR MARKERS:
|
|
16. TESTS RELATED TO LIVER FUNCTION:
|
|
CT ARTERIAL PORTOGRAPHY:
|
|
VASCULAR INVASTION.........:
|
|
BILOBAR DISEASE............:
|
|
LYMPH NODES................:
|
|
SIZE OF DOMINANT TUMOR (MM):
|
|
NUMBER OF TUMORS...........:
|
|
SPIRAL CT:
|
|
INCREMENTAL CT:
|
|
18. DEFINITIVE DIAGNOSIS........:
|
|
19. DATE OF INITIAL DIAGNOSIS...:
|
|
22. DIAGNOSTIC CONFIRMATION.....:
|
|
Print Hepatocellular Cancer PCE
|
|
STAGE OF DISEASE AT DIAGNOSIS
|
|
23. SIZE OF TUMOR...............:
|
|
24. REGIONAL NODES EXAMINED.....:
|
|
25. REGIONAL NODES POSITIVE.....:
|
|
26. AJCC CLINICAL STAGE (cTNM):
|
|
AJCC CLINICAL T............:
|
|
AJCC CLINICAL N............:
|
|
AJCC CLINICAL M............:
|
|
AJCC CLINICAL STAGE GROUP..:
|
|
27. AJCC PATHOLOGIC STAGE (pTNM):
|
|
AJCC PATHOLOGIC T..........:
|
|
AJCC PATHOLOGIC N..........:
|
|
AJCC PATHOLOGIC M..........:
|
|
AJCC PATHOLOGIC STAGE GROUP:
|
|
28. STAGED BY:
|
|
CLINICALLY STAGED BY.......:
|
|
PATHOLOGICALLY STAGED BY...:
|
|
FIRST COURSE OF TREATMENT
|
|
29. DATE OF FIRST COURSE OF
|
|
30. DATE OF INPATIENT ADMISSION.:
|
|
31. DATE OF INPATIENT DISCHARGE.:
|
|
32. DATE OF NON CANCER-DIRECTED
|
|
33. NON CANCER-DIRECTED SURGERY.:
|
|
34. DATE OF CANCER-DIRECTED
|
|
35. SURGICAL APPROACH...........:
|
|
36. SURGERY OF PRIMARY SITE.....:
|
|
37. RADIO-FREQUENCY DESTRUCTION
|
|
OF TUMOR...................:
|
|
39. SURGICAL MARGINS............:
|
|
40. DISTANCE OF TUMOR TO CLOSEST
|
|
41. SURGERY OF OTHER REGIONAL
|
|
OR DISTANT LYMPH NODE(S)...:
|
|
FIRST COURSE...............:
|
|
44. DATE RADIATION STARTED......:
|
|
45. RADIATION THERAPY...........:
|
|
46. DATE CHEMOTHERAPY STARTED...:
|
|
49. ROUTE CHEMOTHERAPY ADMIN....:
|
|
50. CHEMOTHERAPY/SURGERY SEQ....:
|
|
51. DATE OTHER TREATMENT STARTED:
|
|
52. OTHER TREATMENT.............:
|
|
53. ARTERIAL EMBOLIZATION.......:
|
|
54. DEATH WITHIN 30 DAYS OF
|
|
START OF INITIAL COURSE OF
|
|
55. DATE OF FIRST RECURRENCE....:
|
|
56. TYPE OF FIRST RECURRENCE....:
|
|
57. DATE OF LAST CONTACT/DEATH..:
|
|
58. VITAL STATUS................:
|
|
59. CANCER STATUS...............:
|
|
The Class of Case code is not 0, 1, 2 or 5.
|
|
The Behavior Code is not 0, 1 or 3.
|
|
2000 Patient Care Evaluation Study of Primary Intracranial & CNS Tumors
|
|
2000 Patient Care Evaluation Study of Primary Intracranial & CNS Tumors
|
|
10. PRIOR EXPOSURE TO RADIATION
|
|
11. PRIMARY PAYER AT DIAGNOSIS
|
|
12. PRIOR MEDICAL CONDITIONS
|
|
14. GENETIC PREDISPOSITION
|
|
15. USUAL OCCUPATION
|
|
16. USUAL INDUSTRY
|
|
5. DATE OF BIRTH.................:
|
|
9 7. SPANISH ORIGIN................
|
|
403 10. PRIOR EXPOSURE TO RADIATION...
|
|
18 11. PRIMARY PAYER AT DIAGNOSIS....
|
|
12. PRIOR MEDICAL CONDITIONS:
|
|
1202 MULTIPLE SCLEROSIS (MS)......
|
|
354 MYOCARDIAL INFARCTION (MI)...
|
|
1204 CEREBROVASCULAR DISEASE......
|
|
1208 MALIGNANT MELANOMA...........
|
|
1209 OTHER SKIN CANCER............
|
|
1211 COLON OR OTHER GI CANCERS....
|
|
14. GENETIC PREDISPOSITION:
|
|
1214 VON HIPPEL-LINDAU DISEASE....
|
|
1215 TUBEROUS SCLEROSIS...........
|
|
1216 TURCOT SYNDROME..............
|
|
1217 LI-FRAUMENI SYNDROME.........
|
|
1218 KOWDEN DISEASE...............
|
|
1219 NEVOID BASAL CELL CARCINOMA..
|
|
15. USUAL OCCUPATION..............:
|
|
16. USUAL INDUSTRY................:
|
|
17. CLASS OF CASE
|
|
19. NEUROLOGICAL FINDINGS
|
|
20. PRE-THERAPY DIAGNOSTIC STUDIES
|
|
21. TUMOR LOCATION/INVOLVEMENT
|
|
#################### #################### ####################
|
|
#################### #################### ####################
|
|
#################### #################### ####################
|
|
#################### #################### ####################
|
|
#################### #################### ####################
|